GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County,...

GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook
County, Illinois

ATLANTA, June 18 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin
Board: GOVX), an Atlanta-based biopharmaceutical company developing human
vaccines for diseases caused by the HIV-1 (Human Immunodeficiency Virus), and
other infectious agents, announced today that it signed a proposal to discuss
a cooperative arrangement with Cook County Board President Todd H. Stroger and
the Commissioner's of Cook County; the Cook County Health and Hospitals
Systems Board ("Health System"); and the Ruth M. Rothstein's CORE Center's
Foundation, ("Foundation"), that was founded by Cook County, Illinois and Rush
University Medical Center.

Robert T. McNally, President of GeoVax noted, "The proposed arrangement with
Cook County through the Health System and its CORE Foundation has the
potential to advance the fight against HIV/AIDS by accelerating the clinical
trials of the DNA/MVA and MVA/MVA vaccines developed by GeoVax scientists, in
collaboration with scientists at Emory University; the Center for Disease
Control; and the U.S. National Institutes of Health ("the Vaccines")."

Cook County Board President Todd H. Stroger said, "We hope this
ground-breaking proposal, which is dedicated to addressing the need to help
eradicate the HIV/AIDS virus, will extend the opportunity for the residents of
Cook County and the surrounding region to participate in clinical trials of
vaccines with the potential to protect against HIV/AIDS disease." President
Stroger added, "This partnership carries out the mission set forth by our
Health and Hospitals Systems in providing state-of-the-art quality urgent
healthcare to people. It will also assist in accelerating GeoVax's vaccine
program for treatment of patients infected with the HIV virus. We must always
be prepared to adapt to the ever changing needs of society while continuing to
contribute to the overall health and wellness of our world."

The proposal calls for the CEO of Health Systems to consult with the Director
of Health Systems Institutional Review Board and GeoVax to determine whether
to present GeoVax's proposal to the Health Systems Board of Directors for the
purpose of obtaining authorization to negotiate an agreement with GeoVax
regarding its proposal. If agreements adopt the proposal in its present form,
the initial effort of the cooperative program would be focused on accelerating
GeoVax's therapeutic vaccine program for treatment of individuals already
infected with the HIV virus with the Ruth M. Rothstein CORE Center conducting
some of the clinical trials in Cook County. The participation proposed would
contain provisions for seeking and managing funds from private non-profit or
government sources to pay for the clinical trial program. GeoVax would bear
responsibility for production of the vaccine supply, establishment, management
and oversight of the clinical trials process, and regulatory compliance, which
includes interaction with government authorities. There can, however, be no
assurance that agreements will result from the proposal.

HIV/AIDS Background
HIV affects the entire globe and comes in a variety of subtypes. Clade B is
the predominant subtype in North America where there are roughly 60,000 new
infections each year. Globally, there are about 2.5 million AIDS infections
per year, most involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3
million people living with AIDS in North America and 33.2 million people
living with AIDS worldwide. Presently, there is little to prevent HIV
transmission other than education, circumcision, and condoms. It is obvious
from the spread of the disease that these methods are not adequate. Existing
treatments for individuals infected with HIV include anti-retroviral therapies
that are effective but have serious medical side effects and are very
expensive (upwards of $1,500/month). This cost is borne by the individual,
third party insurance, local healthcare, federal or world health
organizations. Development and distribution of an effective HIV/AIDS vaccine
holds great promise. The GeoVax Vaccine would cost a fraction of the cost of
current treatments and, to date, has not elicited serious adverse side
effects. Like commonly used vaccines for polio and measles, if the population
was vaccinated with an effective vaccine, over time, the disease could be
expected to decrease in prevalence to a point where it might essentially
disappear.

About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop,
manufacture, license and commercialize human vaccines for diseases caused by
HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's
AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax AIDS vaccines are designed for use in uninfected people
to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known
as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also
may be effective as therapeutics (treatment of people already infected with
AIDS virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet
Robinson, Senior V.P. of Research and Development, through a collaboration of
colleagues at Emory University's Vaccine Center, the National Institutes of
Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted
by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The
HVTN, funded through a cooperative agreement with the National Institutes of
Health (NIH), is the largest worldwide clinical trials program dedicated to
the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID,
which provided additional support to GeoVax AIDS vaccine development program
with a $15 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement
All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and
assumptions on the date of this press release and are subject to numerous
risks and uncertainties which could cause actual results to differ materially
from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether (i) the Director of the
CEO of Health System (after consultation with the Director of Health System's
Institutional Review Board) determines whether to present the GeoVax proposal
to the Health System's Board, (ii) that the Health System Board will authorize
Health Systems to negotiate an agreement regarding GeoVax's proposals, (iii)
an agreement can be reached, (iv) Health System will request that the
President of the CORE Foundation Board of Directors present the proposal to
its Board in order to seek authorization to negotiate an agreement, (v) if an
agreement is reached with CORE, whether needed funds can be raised, (vi) the
proposed clinical trials will prove helpful to GeoVax's efforts, (vii) GeoVax
can develop and manufacture these vaccines with the desired characteristics in
a timely manner, (viii) GeoVax's vaccines will be safe for human use, (ix)
GeoVax's vaccines will effectively prevent AIDS in humans, (x) vaccines will
receive regulatory approvals necessary to be licensed and marketed, (xi)
GeoVax raises required capital to complete vaccine development, (xii) there is
development of competitive products that may be more effective or easier to
use than GeoVax's products, and (xiii) other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking
statements, and does not intend to do so. Certain matters discussed in this
news release are forward-looking statements involving certain risks and
uncertainties including, without limitation, risks detailed in the Company's
Securities and Exchange Commission filings and reports.

SOURCE GeoVax Labs, Inc.

Robert McNally of GeoVax Labs, Inc., +1-404-727-0971, rmcnally@geovax.com; or
Investor Relations, Leslie Loyet, +1-312-640-6672, lloyet@mww.com, or Media
Relations, Nikki Snodgrass, +1-312-640-6732, nsnodgrass@mww.com, both of
Financial Relations Board, for GeoVax Labs, Inc.